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Diabetic nephropathy (DN) is the leading cause of end-stage renal disease, and its
pathogenesis is complex and has not yet been fully elucidated. Abnormal glucose and
lipid metabolism is key to understanding the pathogenesis of DN, which can develop
in both type 1 and type 2 diabetes. A hallmark of this disease is the accumulation of
glucose and lipids in renal cells, resulting in oxidative and endoplasmic reticulum
stress, intracellular hypoxia, and inﬂammation, eventually leading to glomerulo-
sclerosis and interstitial ﬁbrosis. There is a growing body of evidence demonstrating
that dysregulation of 50 adenosine monophosphateeactivated protein kinase
(AMPK), an enzyme that plays a principal role in cell growth and cellular energy
homeostasis, in relevant tissues is a key component of the development of metabolic
syndrome and type 2 diabetes mellitus; thus, targeting this enzyme may ameliorate
some pathologic features of this disease. AMPK regulates the coordination of
anabolic processes, with its activation proven to improve glucose and lipid homeo-
stasis in insulin-resistant animal models, as well as demonstrating mitochondrial
biogenesis and antitumor activity. In this review, we discuss new ﬁndings regarding
the role of AMPK in the pathogenesis of DN and offer suggestions for feasible clinical
use and future studies of the role of AMPK activators in this disorder.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Diabetes, especially type 2 diabetes, is now a global
epidemic that reﬂects the harmful consequences of modern
lifestyles. Consumption of processed, high-calorie foods, along
with physical inactivity, has created an imbalance between
energy intake and expenditure [1,2]. This disruption of energy
balance is characterized by shifts in lipid and glucose meta-
bolism manifesting as fasting and postprandial hyperglycemiay, Department of Internal
f Medicine, The Catholic
gu, Seoul 137-040, Korea.
ark).
ty of Nephrology. Published b
/4.0/).together with dyslipidemia and is further promoted by insulin
resistance in a number of tissues [3]. Chronic exposure to
glucose overload, free fatty acids, and amino acids can be toxic
[4]. Chronic kidney disease (CKD) associated with diabetes is a
relatively common manifestation, with both the prevalence
and incidence rising in recent years [5]. CKD is the end result of
multifactorial processes that mostly stem from deranged
glucose and lipid metabolism. This is demonstrated by the
increased expression of proteins in relevant signaling pathways
and consistent pathologic renal ﬁndings. Many studies and
experiments have been devised to elucidate the pathogenesis
of these metabolic disruptions, although emerging concepts
related to such ﬁndings remain vast and vague. In an attempt
to unravel the core of this disease entity, a growing body
of evidence shows that dysregulation of 50 adenosiney Elsevier. This is an open access article under the CC BY-NC-ND license
Figure 1. Regulation of AMPK by metabolic stress, LKB1, and intracellular Caþþ. The AMPK signaling pathway responds to energy stresses that cause
ﬂuctuations and imbalances in the AMP/ATP (or ADP/ATP) ratio. As the ATP level falls, there is an increase in the AMP level, which triggers the activation of
the AMPK pathway. The upstream regulator of AMPK, LKB1, allows for AMP phosphorylation at a speciﬁc site (Thr-172) on the a subunit of AMPK. Two other
subunits, STRAD and MO25, form a complex with LKB1 to enhance this process. CaMKK, which is induced by an increase in intracellular Caþþ, is also able to
activate AMPK. Of the CaMKK proteins, CaMKKb has the strongest regulatory effect on AMPK. CaMKKb regulates AMPK in response to changes in sur-
rounding energy stresses.
ACC, acetyl-CoA carboxylase; ADP, adenosine diphosphate; AMP, adenosine monophosphate; AMPK, 50 adenosine monophosphateeactivated protein kinase;
ATP, adenosine triphosphate; CaMKKb, Caþþ/calmodulin-dependent protein kinase kinase b; FoxO3, forkhead box O3; HMGCR, 3-hydroxy-3-metylglutaryl-
CoA reductase; LKB1, liver kinase B-1; MO25, mouse protein 25; mTOR, mammalian target of rapamycin; NAD, nicotinamide adenine dinucleotide; NRF,
nuclear respiratory factor; PGC-1a, peroxisome proliferatoreactivated receptor-gamma coactivator 1a; PFK2, phosphofructokinase 2; PP2A, protein phos-
phatase 2A; PP2C, protein phosphatase 2C; SIRTs, sirtuins; STRAD, STE-related adaptor; Thr-172, threonine-172; TSC2, tuberous sclerosis complex 2.
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tissues is crucial to the development of metabolic syndrome
and diabetes [6]. Therefore, targeting this enzyme is a matter of
great interest, as it may ameliorate some of the pathologic
features of the disease. AMPK regulates the coordination of
anabolic processes with its activation proven to improve
glucose and lipid homeostasis in insulin-resistant animal
models [7,8]. AMPK is strongly expressed in the kidney, where
it is involved in diverse physiological and pathologic processes,
including ion transport, podocyte function, and diabetic renal
hypertrophy. In light of this, we have looked for novel agents
that would help to modulate AMPK in an organ-speciﬁc
manner that targets the diabetic kidney. Instead of providing
an exhaustive review of the role of AMPK in these pathologies,
this review aims to discuss the mechanisms of AMPK agonists
in the context of diabetic nephropathy (DN) and, therefore,
shed light on the risks and beneﬁts of currently available and
promising future AMPK activators as a treatment option.AMPK: structure and mechanism of action
AMPK is a metabolic master switch that regulates down-
stream signals based on shifts in the surrounding energyreservoir [6]. It is expressed in a number of tissues, including
the kidney, the liver, the skeletal muscle, the adipose tissue, and
the hypothalamus of the brain [9,10]. It is activated when
adenosine triphosphate (ATP) consumption causes an increase
in the adenosine monophosphate (AMP)-to-ATP ratio [6]. For
example, under such conditions as hypoglycemia, exercise,
hypoxia, and ischemia, in which accentuated cellular signaling
cascade and intracellular stress arise, consumption of ATP is
suppressed while production is spurred [11]. Regulation of
AMPK activation can be achieved through either allosteric
activation by AMP or stimulation by upstream kinases,
including a compound consisting of 3 proteins: STE-related
adaptor (STRAD), mouse protein 25, and the tumor-suppressor
liver kinase B1 (LKB1) [12]. In addition, other enzymes, such
as Caþþ/calmodulin-dependent protein kinase kinase b
(CaMKKb) [13] and transforming growth factor (TGF) b-acti-
vated kinase [14], also participate in the cellular signaling
cascade (Fig. 1). On activation, AMPK signals through its
downstream substrates to achieve energy homeostasis by
stimulating processes that generate ATP through such actions
as fatty acid oxidation and glucose transport, while inhibiting
those that use ATP through the opposing actions of fatty acid
synthesis and protein synthesis [12]. Thus, the net effect of
AMPK activation is an increased cellular energy level via the
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the stimulation of catabolic, energy-producing pathways [11].
AMPK is a heterotrimer consisting of a catalytic a subunit
(a1 and a2) and regulatory b (b1 and b2) and g subunits (g1, g2,
and g3). Its isoforms are tissue speciﬁc [15]. The g subunit
includes 4 distinct cystathionine beta synthase domains that
perceive shifts in the AMP-to-ATP ratio, conferring the ability to
switch AMPKon and off [16]. The a subunit is a catalytic domain
with its activating loop at threonine-172 (Thr-172) that
switches on as it gets phosphorylated by upstream
AMPK [17]. Ser485 of the subunit exerts its inhibitory action via
phosphorylation by Akt or protein kinase A or by autophos-
phorylation [18]. “ST loop,” a serine/threonineerich insert of
C-terminal domains of the a subunit, appears to contain several
regulatory phosphorylation sites, which block access to up-
stream kinases [16]. AMPK activation can be triggeredwhen the
following conditions are fulﬁlled. First, increased levels of AMP
binding to the g subunit incur conformational change that
exposes the active site Thr-172 on the a subunit, making it a
better substrate for upstream kinases. Second, phosphorylation
of the activating loop of the a subunit by an upstream kinase is
required. This combination of allosteric activation and phos-
phorylation of the stimulatory site leads to the accentuation of
AMPK activity to levels greater than 1,000-fold [15,17].
Activated AMPK then phosphorylates its main downstream
targets, acetyl-CoA carboxylase (ACC) and hydroxy-
methylglutaryl CoA reductase (HMGCR), which are primarily
involved in the rate-limiting steps of lipid homeostasis. Phos-
phorylation at serine 79 (Ser79) exerts inhibitory action by
preventing the conversion of acetyl-CoA to malonyl-CoA,
further encouraging the oxidation of fatty acids. Other down-
stream targets of AMPK include tuberous sclerosis complex
protein-2, which is associated with cell growth and autophagy
[19], and peroxisome proliferatoreactivated receptor-
gamma coactivator-1a (PGC-1a), which hinders protein syn-
thesis by inhibiting the mammalian target of rapamycin
(mTOR) complex 1 [19], in turn inhibiting cholesterol synthesis
and stimulatingmitochondrial biogenesis (Fig.1). Overall, these
downstream targets of AMPK are expected to have favorable
effects on DN by maintaining metabolic homeostasis.
The role of AMPK beyond energy homeostasis:
regulating metabolism
AMPK plays a major role in glucose homeostasis by modu-
lating glucose transport in peripheral tissues [20]. Skeletal
muscle, one of the main peripheral tissues involved in glucose
uptake and disposal, expresses glucose transporter type 4
(GLUT4). In hyperglycemia, insulin promotes the translocation
of intracellular vesicular GLUT4 to the cell membrane, thereby
increasing glucose uptake in the muscle [6]. AMPK activation
contributes to glucose transport in a similar way as insulin. The
result is AMPK-induced glucose uptake stimulation in skeletal
cells, with increased expression of enzymes specialized in
glucose uptake such as GLUT4 and hexokinase II [6]. Moreover,
AMPK directly phosphorylates the GLUT4 enhancer factor that
is essential in the regulation of GLUT4 expression. Hexokinase
phosphorylates glucose entering the cell, allowing for a struc-
tural change that prevents glucose from leaving the cell in the
ﬁrst step of glycolysis. Overall, these sequential alterations in
the expression of enzymes involved in glucose uptake are the
ultimate result of AMPK activation, which stimulates catabolicprocesses that counter the deleterious effects of glucose excess
and maintains energy homeostasis.
Hyperglycemia is a causative factor in the development of
DN through its detrimental effects on glomerular andmesangial
cells. Some in vitro studies have demonstrated its association
with mesangial cell proliferation and hypertrophy, along with
increased matrix production and basement membrane thick-
ening [21]. Moreover, hyperglycemia-induced upregulation of
vascular endothelial growth factor expression in podocytes in-
creases vascular permeability [21]. In addition to these changes,
classical pathways involving the production of advanced
glycosylation end products, activation of protein kinase C, and
reinforcement of the aldose reductase pathway contribute to
the development of DN, inwhich oxidative stress appears to be a
common theme [22,23]. In this regard, targeting AMPK in DN
could ameliorate these adverse effects by regulating glucose-
induced oxidative stress metabolism [4]. There is growing evi-
dence regarding the role of AMPK in mediating intracellular
signaling pathways, that is, the alteration of cellular redox state
and antioxidant enzyme expression via the AMPK transcrip-
tional activity of class O forkhead box (FoxO) signaling pathway
[23]. FoxO proteins are an evolutionary conserved subfamily of
transcriptional factors involved in the regulation of energy
metabolism. In detail, it increases the expression of antioxidant
enzymes, promotes mitochondrial biogenesis, cell survival, and
longevity in several tissues, and even participates in tumor
suppression [22]. The transcriptional activity of FoxO3a, one of
the 4 members of the family consisting of FoxO1, FoxO3, FoxO4,
and FoxO6, is further modulated by AMPK in response to
metabolic stress. Moreover, FoxO3a is known to shield quies-
cent cells from reactive oxygen species (ROS) by antagonizing
apoptosis through which oxidative stress is reduced by directly
increasing their quantities of manganese superoxide dismutase
(SOD)messenger RNA and protein [21]. It is well known that the
activity of autophatic process is closely related to changes in the
production of ROS. Although mild oxidative stress-induced
autophagic process is beneﬁcial for cell survival, excessive
oxidative damage caused by high ROS would bypass autophagy
induction and evoke apoptosis or necrosis, leading to promote
cell death [24]. Antioxidant enzymes, including thioredoxin,
peroxiredoxin, Mn-SOD, and catalase, are found to be upregu-
lated on activation of the AMPKeFoxO3a signaling pathway
[25]. Therefore, on ROS exposure, AMPK, silent information
regulator T1 (SIRT1), awell-known FoxO3a coactivator [26], and
FoxO3a are expected to intertwine closely to regulate the
apoptotic and autophagy crosstalk [22].
AMPK modulates changes in lipid metabolism via the
regulation of fatty acid oxidation and cholesterol synthesis in
the liver. The key enzymes involved include ACC and HMGCR
[27,28]. Both participate in the rate-limiting steps of fatty acids
and cholesterol synthesis and are inactivated on phosphory-
lation by AMPK. Catabolism is induced by fatty acid beta-
oxidation, leading to the production of acetyl-CoA, which
then joins the citric acid cycle to generate ATP. On the other
hand, fatty acid synthesis is a multistep, energy-consuming,
anabolic process that generates fatty acids from acetyl-CoA
and malonyl-CoA. Likewise, cholesterol is synthesized from
acetyl-CoA to produce 3-hydroxy-3-methylglutaryl-coenzyme A
(HMGCoA), which is then converted into mevalonate through
an anabolic process that consumes ATP. Hence, in response to
energy depletion, the inhibition of ACC by AMPK results in a
fall in malonyl-CoA levels and subsequently interrupts fatty
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oxidation. Through the activation of malonyl-CoA decarbox-
ylase, AMPK brings about a decrease in malonyl-CoA levels and
an increase in fatty acid oxidation. Likewise, HMGCR is inac-
tivated on phosphorylation, which leads to a reduction in
cholesterol synthesis. In addition, the expression of such genes
as fatty acid synthase, pyruvate kinase, ACC, and sterol regu-
latory elementebinding protein-1 (SREBP-1) is lipogenesis
associated and suppressed by AMPK in states of energy deﬁcit
[29].
Emerging evidence indicates that renal lipid dysregulation is
a major causative factor in the development of CKD, along with
DN [30]. Recently, it has been characterized by tubular rather
than glomerular lipid accumulation, attributable to decreased
lipid uptake, increased renal lipid synthesis, and defective fatty
acid utilization in the renal physiology [19]. Systemic and
intrarenal alterations in lipid metabolism are reﬂected by
increased triglycerides and low-density lipoprotein levels,
decreased high-density lipoprotein levels, increased expression
of SREBP-1 and fatty acid synthase, and decreased expression of
carnitine palmitoyltransferase I, which is involved in the rate-Figure 2. Representative signaling in the AMPK pathway by various AMPK
activators on mitochondrial biogenesis, glucose and lipid metabolism, and anti
AICAR, 5-aminoimidazole-4-carboxamide ribonucleoside; AMP, adenosine mono
ATP, adenosine triphosphate; CaMKKb, Caþþ/calmodulin-dependent protein kin
mTOR, mammalian target of rapamycin; NAD, nicotinamide adenine dinucleotid
receptor-gamma coactivator 1a; SIRT1, silent information regulator T1.limiting step of fatty acid oxidation [31]. AMPK inhibits lipo-
genesis and enhances fatty acid oxidation through targets such
as SREBP, ACC, fatty acid synthase, and 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMGR) in various tissues. This raises
the potential for AMPK activation as a therapeutic target in
optimizing lipid metabolism in DN [32].
AMPK perceives shifts in the surrounding energy
reservoir and adapts to the nutrient supply status by promoting
a cellular response. It participates in protein synthesis by
regulating protein translation. Its main targets are cytoplasmic
substrates, such as eukaryotic elongation factor 2 and mTOR,
which modulate the stimulation of cellular processes that aid
cell growth in states of nutritional surplus [33]. On AMPK-
dependent phosphorylation of these substrates, repression of
protein synthesis ensues. It could be useful to coordinate these
processes in DN as they correlate with diminished AMPK
activity, resulting in increases in protein synthesis that can
cause diabetes-induced renal hypertrophy in hyperglycemic
conditions. Thus, speciﬁcally stimulating cytoplasmic AMPK
could provide a more focused approach in alleviating diabetes-
induced renal damage [34].activators. Schematic diagram of selected physiological effects of AMPK
tumor activity.
phosphate; AMPK, 50 adenosine monophosphateeactivated protein kinase;
ase kinase b; FoxOs, forkhead transcription factors; LKB1, liver kinase B-1;
e; NF-kB, nuclear factor kappaB; PGC-1a, peroxisome proliferatoreactivated
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In parallel with a vast and rapidly growing body of
knowledge on the favorable effects of AMPK, of which only a
fragment has been discussed, investigators have devised
several pharmaceutical agents in the search for naturally
occurring compounds that could activate AMPK with minimal
toxicity. We will introduce some conventional AMPK activa-
tors, along with our data on new therapeutic agents used to
experimentally treat diabetic mouse models addressing DN
(Figs. 2, 3).
Conventional AMPK activators
5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR)
is an adenosine analogue that is frequently demonstrated in
animal models as it recapitulates AMP in the course of being
metabolized to phosphorylated AICA riboside or AICA ribotide
[AICAR 5-monophosphate (ZMP)] (Fig. 2) [35]. ZMP binding to
the g subunit of AMPK directly activates AMPK via 3 mecha-
nisms: accelerating phosphorylation, inhibiting dephosphory-
lation, and allosterical activation [35,36]. AICAR upregulates
genes associated with oxidative metabolism, angiogenesis, and
glucose sparing, thereby improving glucose homeostasis in
obese, insulin-resistant rats [37]. Moreover, a recent report onFigure 3. Proposed renoprotective mechanisms in diabetic nephropathy b
reduces albuminuria, glomerulosclerosis, and tubulointerstitial ﬁbrosis in ty
biogenesis, peroxisomal b-oxidation, oxidative stress, and lipogenesis through
AICAR, 5-aminoimidazole-4-carboxamide ribonucleoside; AMPK, 50 adenosine m
elementebinding protein; ECM, extracellular matrix; FoxOs, forkhead transcr
tivator 1a; PPARs, peroxisome proliferatoreactivated receptors; SIRT1, silent inchronic AICAR treatment shows its efﬁcacy in preventing un-
favorable functional and morphologic changes in mice raised
on high-fat diets, with regard to renal cholesterol and phos-
pholipid accumulation and lysosomal system dysfunction; this
demonstrates that AICAR in a viable form may be a promising
agent in alleviating the deleterious outcomes of DN [38].
Metformin's pluripotent roles are alluded to in terms of its
antitumorigenic, glucose-lowering, and cardioprotective ef-
fects, which are due in part to its upregulation of AMPK activity
[39,40]. Metformin's glucose-lowering effect is a result of
reduced hepatic gluconeogenesis, whereas improved insulin
sensitivity is mediated by the activation of the LKB1eAMPK
axis [41]. It is suggested that metformin activates AMPK indi-
rectly by inhibiting relevant cells from entering the mito-
chondrial respiratory chain, facilitating a switch from aerobic to
anaerobic glycolysis in a manner that raises the cellular AMP-
to-ATP ratio (Fig. 2) [42]. In addition, mounting evidence in-
dicates that metformin-induced inactivation of mTOR by AMPK
is associated with suppressed cell proliferation and increased
autophagy, which are thought to lower cancer incidence [43].
Stimulation of AMPK activity with AICAR or metformin also
resulted in inhibition of renal hypertrophy due in part to
the prevention of glucose-induced protein synthesis. This
was associated with decreases in the phosphorylation of Akt,
mTOR, p70S6 kinase, and 4E-BP1 in renal cells, suggestingy known and novel AMPK activators. Treatment with AMPK activators
pes 1 and 2 diabetic nephropathy by exerting effects on mitochondrial
the activation of AMPK-SIRT1 signaling.
onophosphateeactivated protein kinase; ChREBP, carbohydrate regulatory
iption factors; PGC-1a, peroxisome proliferator–activated receptorg coac-
formation regulator T1; SREBP, sterol regulatory elementebinding protein.
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translation [44].
Adiponectin, an adipose tissue-derived cytokine, is another
AMPK activator. Decreases in the plasma level of adiponectin
have been correlated with insulin resistance and obesity. In
diabetes, reduced AMPK activity was noted to be associated
with the renal accumulation of triglyceride and glycogen,
which reﬂects the pathogenesis of diabetic renal hypertrophy
[45]. Furthermore, adiponectin knockout mice exhibit
increased albuminuria and fusion of the podocyte foot process
[46]. In cultured podocytes, both adiponectin and AMPK acti-
vation reduced podocyte permeability to albumin, further
ameliorating podocyte dysfunction. These effects are mostly
due to the reduction of oxidative stress, with subsequent de-
creases in the level of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase 4 in podocytes [46]. Another study
showed that adiponectin receptor 1 and catalytic AMPK sub-
units a1 and a2 were localized to the glomeruli in endothelial,
mesangial, podocyte, and parietal epithelial cells of
Bowman capsule. The incubation of freshly isolated glomeruli
with adiponectin led to the activation of AMPK via phosphor-
ylation of its catalytic domain [47].
Resveratrol is a naturally occurring plant polyphenol that
may target aging and obesity-related chronic diseases by pre-
venting inﬂammation and oxidative stress [48]. It activates
SIRT1, a nicotinamide adenine dinucleotideedependent pro-
tein deacetylase, and AMPK (Fig. 2). Resveratrol's subsequent
activation of downstream targets is expected to have some
renoprotective effects involving changes in catabolic meta-
bolism, mitochondrial activation, and angiogenesis, as well as
enhanced cell survival [49e51]. Resveratrol's renoprotective
effects with regard to oxidative stress and proinﬂammatory
reactions are demonstrated in the attenuation of diabetes-
induced superoxide anion, protein carbonyl levels, and cyto-
kines interleukin-1b, tumor necrosis factor-a, and interleukin-
6, which are associated with increased AMPK phosphorylation
in diabetic renal tissues [52]. Moreover, in our previous
experiment, db/db mice treated with resveratrol demonstrated
improvements in not only renal functional parameters but also
pathologic features. This manifestation was consistent with
increases in the phosphorylation of AMPK, activation of
SIRT1ePGC-1a signaling, and activation of the key downstream
effector, PPARaeestrogen-related receptor (ERR)-1aeSREBP-1c.
In addition, resveratrol reduced the activity of
phosphatidylinositol-3 kinase-Akt phosphorylation and
FoxO3a phosphorylation, which further caused a decrease in B-
cell leukemia/lymphoma 2 (BCL-2)eassociated X protein and
increases in BCL-2, SOD1 and SOD2 production. In cultured
mesangial cells, resveratrol attenuated renal apoptotic changes
further, preventing high-glucose-induced oxidative stress and
apoptosis through the phosphorylation of AMPK and activation
of SIRT1–PGC-1a signaling and the downstream effector,
PPARa–ERR-1a–SREBP1c. The results suggest that resveratrol
prevents DN in db/db mice through the phosphorylation of
AMPK and activation of SIRT1ePGC-1a signaling, which seem
to prevent lipotoxicity-related apoptosis and oxidative stress in
the kidney [8].
New AMPK activators
Fenoﬁbrate is a drug of the ﬁbrate class used for the treat-
ment of dyslipidemia [53] but is also an agent that couldalleviate DN-induced alterations through AMPK activation
(Fig. 2). Streptozotocin-induced diabetic rats treated with
fenoﬁbrate improved in not only renal functional
parameters but also hyperglycemia-induced oxidative damage,
as indicated by signiﬁcantly increased levels of glutathione and
catalase together with a noticeable decrease in lipid peroxi-
dation. Fenoﬁbrate's protective role in DN is in ameliorating
endothelial dysfunction via increased modulation of AMPK,
LKB1, and endothelial nitric oxide synthase (eNOS) expression
[54]. In parallel with this, our previous experiments on the
diabetic mouse model have demonstrated that fenoﬁbrate can
ameliorate albuminuria, glomerular matrix expansion, and in-
ﬂammatory cell inﬁltration in the glomeruli and inhibit the
accumulation of intrarenal free fatty acids and triglycerides.
These results are compatible with the increased expression of
PPARa and the activation of AMPK, PGC1a-ERR1a-pACC, as well
as the suppression of SREBP-1c and carbohydrate regulatory
elementebinding protein-1, which constitutes the main
downstream effector in lipid metabolism. Fenoﬁbrate
decreased the phosphorylation of phosphatidylinositol-3 ki-
nase-Akt and FoxO3a in the kidneys, resulting in the demon-
strated BCL-2-to-BCL-2eassociated X protein ratio and SOD1
levels. Such ﬁndings were reproducible in cultured mesangial
cells as reﬂected by the prevention of high-glucoseeinduced
apoptosis and oxidative stress via AMPK phosphorylation, PGC-
1a-ERR-1a activation, and SREBP-1c and carbohydrate regula-
tory elementebinding protein-1 suppression. Our results sug-
gest that fenoﬁbrate's potential as a therapeutic modality for
DN lies in its ability to improve lipotoxicity by stimulating
AMPK-PGC-1a-ERR-1a-FoxO3a signaling [55].
Anthocyanin, a ﬂavonoid in the polyphenol class, is a major
constituent of food color and has been reported to possess both
antidiabetic and antioxidant properties [56]. As its beneﬁcial
effects on lipid metabolism are dependent on AMPK activation
(Fig. 2) [57], we were prompted to investigate whether an
anthocyanin-rich Seoritae extract could ameliorate DN in db/db
mice. Indeed, anthocyanin ameliorated intrarenal lipid accu-
mulation with attenuations of mesangial expansion and
glomerular inﬂammation; these effects appear to be attribut-
able to the increased phosphorylation of AMPK, activation of
PPARa and peroxisome proliferatoreactivated receptor-
gamma, and inhibitory activity of ACC and SREBP-1c, leading to
a reduction in lipotoxicity in the kidney. In cultured human
glomerular endothelial cells, anthocyanin prevented high-
glucoseeinduced oxidative stress and apoptosis via activation
of AMPK in the same manner. The results indicate that antho-
cyanin could help alleviate some of the pathologic features of
DN as it prevents lipotoxicity-related apoptosis and oxidative
stress in the diabetic kidney through the activation of AMPK
and its downstream effectors [58].
Cinacalcet is a calcimimetic that positively modulates the
calcium-sensing receptor (CaSR). It is mainly used in the
treatment of secondary hyperparathyroidism in CKD patients as
it both diminishes the inhibitory effect of parathyroid hormone
on renal phosphate reabsorption and inhibits renal calcium
excretion [59]. However, some recent reports have demon-
strated that CaSRs are expressed in human endothelial cells and
that their stimulation by cinacalcet induces nitric oxide (NO)
production, resulting in vasorelaxation [60]. Moreover,
calcimimetics signiﬁcantly increased intracellular Caþþ levels,
which in turn augmented NO release via a time- and Caþþ-
dependent increase in eNOS-ser1177 phosphorylation activity
Kim and Park / AMPK in diabetic nephropathy 75[61]. Based on these ﬁndings, we proposed that DN-induced
endothelial dysfunction could be ameliorated by the activa-
tion of eNOSeNO as a result of cinacalcet administration
(unpublished observations). Our preliminary work shows that
cinacalcet reduced albuminuria without inﬂuencing either
blood glucose or Caþþ concentration and ameliorated mesan-
gial expansion and inﬂammatory cell inﬁltration in the
glomerulus of db/db mice. In the renal cortex, cinacalcet
increased the expression of CaSR and the phosphorylation of
CaMKKb and LKB1. Subsequent activation of AMPK was fol-
lowed by the activation of PGC-1a and phospho-Ser1177
eNOSeNO (Fig. 2). In vitro studies were consistent with the
fact that cinacalcet decreases oxidative stress and apoptosis;
this effect is attributable to increases in intracellular Caþþ and
the phosphorylation of CaMMKb, LKB1, and AMPK. All these
changes were associated with an increase in the phosphoryla-
tion of eNOS. Overall, our results suggest that cinacalcet in-
creases intracellular Caþþ, subsequently activating the
CaMKKbeLKB1eAMPK signaling pathway in the kidney. This
increase and activation of relevant molecules ameliorates renal
damage, potentially providing a therapeutic modality for DN.
AdipoRon is an orally active, synthetic small molecule that
activates adiponectin receptor (AdipoR). It mimics the antidia-
betic effects of adiponectin, exhibiting its effect through the
activation of AMPK and PPARa pathways via AdipoR1 and Adi-
poR2, respectively (Fig. 2) [62]. AdipoR activation has recently
become a promising treatment for diabetes, nonalcoholic fatty
liver disease, and cardiovascular disease, demonstrating anti-
inﬂammatory actions in macrophages and cytoprotective ef-
fects on pancreatic b-cells [63]. However, mice overexpressing
adiponectin are found to have reduced bone density [64], heart
damage (left ventricular hypertrophy) [65], increased angio-
genesis and adipogenesis [65], and infertility [66]. Despite these
concerns, AdipoRon appears to be weight neutral and actually
prolongs the life span in db/dbmice [62]. Our unpublished data
suggest that AdipoRon-treated db/db mice exhibit improve-
ments in DN associated with increased expression of AdipoR1
and AdipoR2 in the glomerulus and consistent upregulation of
phosphorylated AMPK, PPARa, and their downstream target
molecules (unpublished observations). With respect to renal
ultrastructure, AdipoRon treatment is associated with a
noticeable reversal of diabetes-induced glomerular basement
membrane (GBM) thickening, foot process widening, and slit
diaphragm space narrowing; furthermore, it decreased
glomerular matrix expansion and inﬂammation. AdipoRonmay
control oxidative stress in the glomerulus through AMPK- and
PPARa-activated pathways, helping to prevent the deterioration
of renal function. The protective role of AdipoRon against the
development of albuminuria appears to occur through direct
action on podocytes, independent of the systemic effects of
adiponectin. Its reduction of oxidative stress confers protection
against albuminuria and podocyte damage, ameliorating
endothelial dysfunction in DN. Therefore, AdipoRon is a novel,
promising therapeutic agent in preventing and ameliorating
DN, particularly in type 2 diabetes.
Conclusion and future perspectives
Despite progress in the ﬁeld of pharmacologic therapies that
aims to prevent or delay the progression of DN, the number of
end-stage renal disease patients is rising steadily, especially in
Korea [5,67]. Therefore, the development of new therapeuticagents is of crucial concern to public health. Mounting evidence
suggests that AMPK activation in various tissues can help ach-
ieve metabolic homeostasis, with subsequent improvements in
glucose and lipid proﬁles. We have summarized the role of
AMPK activation in the context of several known and new ac-
tivators that can treat DN by preventing renal ﬁbrosis, extra-
cellular matrix accumulation, apoptosis, and inﬂammation in
the kidney (Fig. 3). However, a major pitfall in the use of AMPK
activators is their as-yet-unknown adverse effects, which may
counter the therapeutic effects we are aiming for. Such off-
target effects involve AMPK's possible role in the stimulation
of food intake through the activation of AMPK expressed in
certain nuclei of the hypothalamus [68]. This provides a clear
example of the need for both target and tissue speciﬁcity.
Pharmacologic activation of AMPK needs to be achieved tissue
speciﬁcally, and the isoforms of AMPK expressed in different
tissues need to be identiﬁed [69]. In addition, we must deter-
mine the effective dose with least toxicity that can still produce
detectable AMPK activation to achieve adequate metabolic
regulation. The evidence of the metabolic effects of AMPK sig-
niﬁes just the beginning of the ﬁeld, with signiﬁcant challenges
lying ahead in the translation of these data into feasible thera-
peutics for DN and obesity-related metabolic disease [5].
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